Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Commission (EC) has granted marketing authorization for DUPIXENT®(dupilumab), for use in adults with

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

New User Registration
 
 
 
 
 
 
 
 
 
Please indicate that you agree to the Terms of Service *
*Required field